Compare RYN & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RYN | AMRX |
|---|---|---|
| Founded | 1926 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 5.8B |
| IPO Year | 1994 | 2018 |
| Metric | RYN | AMRX |
|---|---|---|
| Price | $21.57 | $18.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $26.00 | $15.60 |
| AVG Volume (30 Days) | ★ 2.1M | 1.8M |
| Earning Date | 05-06-2026 | 05-01-2026 |
| Dividend Yield | ★ 11.73% | N/A |
| EPS Growth | 26.78 | ★ 157.89 |
| EPS | N/A | ★ 0.19 |
| Revenue | ★ $484,485,000.00 | N/A |
| Revenue This Year | $214.97 | $4.48 |
| Revenue Next Year | $10.35 | $7.13 |
| P/E Ratio | ★ N/A | $96.42 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $19.49 | $7.99 |
| 52 Week High | $27.34 | $19.26 |
| Indicator | RYN | AMRX |
|---|---|---|
| Relative Strength Index (RSI) | 50.52 | 65.29 |
| Support Level | $20.98 | $12.46 |
| Resistance Level | $21.85 | N/A |
| Average True Range (ATR) | 0.56 | 0.58 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 38.93 | 82.42 |
Rayonier Inc is a timberland real estate investment trust engaged in the ownership, management, and investment of timberlands. The company operates through Southern Timber, Pacific Northwest Timber, and Real Estate segments. The Southern Timber and Pacific Northwest Timber segments are involved in harvesting timber and related activities, as well as value-added services such as licensing properties for hunting, leasing land for mineral extraction and communication infrastructure, land-based solutions including carbon capture and solar energy, and log trading. The Real Estate segment is engaged in land sales across various categories, as well as residential and commercial leasing activities. It generates the majority of its revenue from the Southern Timber segment.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.